Fully Human Single-Domain Antibodies Against SARS-CoV-2

doi 10.1101/2020.03.30.015990
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain

2020English

Potent Human Monoclonal Antibodies Against SARS CoV, Nipah and Hendra Viruses

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2009English

Detection of Antibodies Against SARS-CoV-2 in Patients With COVID-19

Journal of Medical Virology
VirologyInfectious Diseases
2020English

On the Interactions of the Receptor-Binding Domain of SARS-CoV-1 and SARS-CoV-2 Spike Proteins With Monoclonal Antibodies and the Receptor ACE2

2020English

Human Monoclonal Antibodies Block the Binding of SARS-CoV-2 Spike Protein to Angiotensin Converting Enzyme 2 Receptor

2020English

Monoclonal Antibodies for the S2 Subunit of Spike of SARS-CoV Cross-React With the Newly-Emerged SARS-CoV-2

2020English

Human ACE2 Receptor Polymorphisms Predict SARS-CoV-2 Susceptibility

2020English

Hypothesis: Advanced Biotechnological Treatment Approaches Against SARS-CoV-2 (COVID-19)

Volume 5 - 2020, Issue 4 - April
2020English

SARS-COV-2 and Infectivity

Journal of Medical Virology
VirologyInfectious Diseases
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy